ABT Valuation Metrics
ABT Stock Price Metrics
ABT Dividend Metrics
ABT Growth Rate Metrics
ABT Discounted Cash Flow Metrics
| Fair Value Price | $149.08 |
| Margin of Safety | 67.87% |
ABT Revenue Metrics
ABT PE Ratio Metrics
| PE Ratio | 24.74 |
| PE Ratio Avg TTM | 19.30 |
| PE Ratio Avg 3Y | 27.88 |
| Current VS TTM Avg | +28.21% |
| Current VS 3Y Avg | -11.26% |
| Current VS 5Y Avg | -12.26% |
ABT PS Ratio Metrics
| PS Ratio | 3.44 |
| PS Ratio Avg TTM | 4.75 |
| PS Ratio Avg 3Y | 4.81 |
| Current VS TTM Avg | -27.52% |
| Current VS 3Y Avg | -28.41% |
| Current VS 5Y Avg | -28.05% |
ABT PB Ratio Metrics
| PB Ratio | 2.98 |
| PB Ratio Avg TTM | 4.07 |
| PB Ratio Avg 3Y | 4.66 |
| Current VS TTM Avg | -26.84% |
| Current VS 3Y Avg | -36.04% |
| Current VS 5Y Avg | -41.52% |
ABT Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 21.03 |
| PFCF Ratio Avg TTM | 29.78 |
| PFCF Ratio Avg 3Y | 33.51 |
| Current VS TTM Avg | -29.38% |
| Current VS 3Y Avg | -37.25% |
| Current VS 5Y Avg | -29.36% |
ABT Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.29 |
| Debt/Equity Ratio Avg TTM | 0.30 |
| Debt/Equity Ratio Avg 3Y | 0.38 |
| Current VS TTM Avg | -4.92% |
| Current VS 3Y Avg | -23.18% |
| Current VS 5Y Avg | -34.59% |
ABT PEG Ratio Metrics
| PEG Ratio | 3.01 |
| PEG Ratio Avg TTM | 3.01 |
| PEG Ratio Avg 3Y | 3.01 |
| Current VS TTM Avg | 0.00% |
| Current VS 3Y Avg | 0.00% |
| Current VS 5Y Avg | 0.00% |
ABT FCF Yield
| FCF Yield | 4.76% |
| FCF Yield Avg TTM | 3.47% |
| FCF Yield Avg 3Y | 3.07% |
| Current VS TTM Avg | +37.29% |
| Current VS 3Y Avg | +55.21% |
| Current VS 5Y Avg | +35.74% |
ABT Earnings Yield
| Earnings Yield | 4.04% |
| Earnings Yield Avg TTM | 5.50% |
| Earnings Yield Avg 3Y | 4.05% |
| Current VS TTM Avg | -26.54% |
| Current VS 3Y Avg | -0.31% |
| Current VS 5Y Avg | +4.42% |
ABT EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 22.24 |
| Ev/Ebit Ratio Avg TTM | 27.99 |
| Ev/Ebit Ratio Avg 3Y | 30.33 |
| Current VS TTM Avg | -20.53% |
| Current VS 3Y Avg | -26.68% |
| Current VS 5Y Avg | -20.18% |
ABT EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 16.88 |
| Ev/Ebitda Ratio Avg TTM | 18.72 |
| Ev/Ebitda Ratio Avg 3Y | 19.30 |
| Current VS TTM Avg | -9.84% |
| Current VS 3Y Avg | -12.52% |
| Current VS 5Y Avg | -9.14% |
ABT EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.65 |
| Ev/Assets Ratio Avg TTM | 2.50 |
| Ev/Assets Ratio Avg 3Y | 2.67 |
| Current VS TTM Avg | -34.06% |
| Current VS 3Y Avg | -38.27% |
| Current VS 5Y Avg | -39.98% |
ABT EV/Sales Ratio Metrics
| Ev/Sales Ratio | 4.04 |
| Ev/Sales Ratio Avg TTM | 4.94 |
| Ev/Sales Ratio Avg 3Y | 5.00 |
| Current VS TTM Avg | -18.27% |
| Current VS 3Y Avg | -19.27% |
| Current VS 5Y Avg | -18.91% |
ABT Current Ratio Metrics
| Current Ratio | 1.58 |
| Current Ratio Avg TTM | 1.63 |
| Current Ratio Avg 3Y | 1.63 |
| Current VS TTM Avg | -2.77% |
| Current VS 3Y Avg | -3.07% |
| Current VS 5Y Avg | -6.05% |
ABT Quick Ratio Metrics
| Quick Ratio | 1.18 |
| Quick Ratio Avg TTM | 1.21 |
| Quick Ratio Avg 3Y | 1.20 |
| Current VS TTM Avg | -2.07% |
| Current VS 3Y Avg | -1.67% |
| Current VS 5Y Avg | -6.35% |
ABT ROIC Metrics
| ROIC | 8.43% |
| ROIC Avg 3Y | 9.70% |
| ROIC Avg 5Y | 9.86% |
| Current VS 3Y Avg | -13.05% |
| Current VS 5Y Avg | -14.46% |
| Current VS 10Y Avg | +11.33% |
ABT Return on Assets Metrics
| ROA | 7.52 |
| ROA Avg TTM | 11.99 |
| ROA Avg 3Y | 10.28 |
| Current VS TTM Avg | -37.28% |
| Current VS 3Y Avg | -26.83% |
| Current VS 5Y Avg | -20.44% |
ABT Return on Equity Metrics
| ROE | 12.51 |
| ROE Avg TTM | 20.32 |
| ROE Avg 3Y | 18.59 |
| Current VS TTM Avg | -38.42% |
| Current VS 3Y Avg | -32.71% |
| Current VS 5Y Avg | -30.38% |
ABT Net Profit Margin Metrics
| Net Profit Margin | 14.72% |
| Net Profit Margin Avg TTM | 23.34% |
| Net Profit Margin Avg 3Y | 19.20% |
| Current VS TTM Avg | -36.92% |
| Current VS 3Y Avg | -23.35% |
| Current VS 5Y Avg | -16.86% |
Last Updated: Wednesday, June 10, 2026
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford